Working…
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered SARS-CoV-2.
Protect yourself and others from infection by washing your hands, wearing masks or using an alcohol based rub frequently and not touching your face.

CUReD:  CSIR Ushered Repurposed Drugs -  A website that provides information on CSIR Partnered Clinical Trials.

   Details of Umifenovir

Name of trial Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients.
CSIR lab/s involved Industry Sponsor/s & Scientific Collaborator/s Clinical Trial Site/s
CSIR-CDRI

 

 M/s Medizest Pharmaceuticals Pvt Ltd.

King George’s Medical University, Ram Manohar Lohia Institute of Medical Sciences, Eras Lucknow Medical College and Hospital, Lucknow
Type of Drug Antiviral
IP Status of Drug/s
Out of IP
Mechanism of Action & Scientific rationale for Covid-19

1. Broad spectrum antiviral agent

2. Prevents viral entry into human host cells

3. Host targeting agent
Combinations therapy or monotherapy Combination therapy with ‘Standard of care’
Trial design

Health Condition / Problems Studied

 Health Type Condition
COVID19 patients

Mild and moderate symptoms     

Number of trial sites       

Number of arms              

Number of patients         

03
02
132
Click here for End points (primary and secondary)
Status of the CSIR trial
Patient recruitment has been initiated
Name & details of Clinical PI/s Dr. VirendraAtam, KGMU, Lucknow, Dr. Vikram Singh, RMLIMS, Lucknow, Dr. MMA Faridi, Eras Medical College, Lucknow, Dr. Vivek Bhosale, CSIR-CDRI,

Administrative PI and Nodal scientist: Dr. R. Ravishankar, CSIR-CDRI, Lucknow

Prof. Tapas K. Kundu, Director, CSIR-CDRI

Back